ON THIS PAGE: You will find information about how many people are diagnosed with this type of cancer each year and some general survival information. Remember, survival rates depend on several factors. To see other pages, use the menu on the side of your screen.
This year, an estimated 2,970 people of all ages (1,640 men and boys and 1,330 women and girls) in the United States will be diagnosed with bone cancer. It is estimated that 1,490 deaths (850 men and boys and 640 women and girls) from this disease will occur this year. Primary bone cancer accounts for less than 0.2% of all cancers.
In adults, chondrosarcoma makes up more than 40% of primary bone cancers, followed by osteosarcoma (28%), chordoma (10%), Ewing sarcoma (8%), and UPS/fibrosarcoma (4%). The remaining types of bone cancer are rare. In teens and children, osteosarcoma and Ewing sarcoma are more common.
The five-year survival rate is the percentage of people who survive at least five years after the cancer is found. The five-year survival rate of adults and children for all types of bone cancer combined is about 70%. For adults with chondrosarcoma, the five-year survival rate is about 80%.
Cancer survival statistics should be interpreted with caution. These estimates are based on data from thousands of people with this type of cancer in the United States each year, so the actual risk for a particular individual may be different. It is not possible to tell a person how long he or she will live with bone cancer. Because the survival statistics are measured in five-year intervals, they may not represent advances made in the treatment or diagnosis of this cancer. Learn more about understanding statistics.
Statistics adapted from the American Cancer Society's (ACS) publication, Cancer Facts and Figures 2015, and the ACS website.
The next section in this guide is Medical Illustrations and it offers drawings of body parts often affected by this disease. Or, use the menu on the left side of your screen to choose another section to continue reading this guide.